Biohaven Pharmaceuticals
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Biohaven Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).
Biohaven Pharmaceuticals: 12 sponsored US clinical trials, none currently recruiting.
Biohaven Pharmaceuticals sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 7 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Spinocerebellar Ataxias, with 2 trials.
Top-decile sponsor footprint
Biohaven Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
9 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
12 total, page 1 of 1
A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
NCT05337553
Troriluzole in Adult Participants With Spinocerebellar Ataxia
NCT03701399
Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients
NCT04634435
Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder
NCT04708834
Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder
NCT04693351
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
NCT04641143
Study of BHV-3241 in Participants With Multiple System Atrophy
NCT03952806
Randomized Trial of Adult Participants With Generalized Anxiety Disorder
NCT03829241
Study of BHV-4157 in Alzheimer's Disease
NCT03605667
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
NCT03520517
Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder
NCT03299166
Trial in Adult Participants With Spinocerebellar Ataxia (SCA)
NCT02960893
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 3 |
| Phase 3 | 7 |
Therapeutic Areas
How the Biohaven Pharmaceuticals archive is shaped
12 indexed studies, none listed as recruiting (0% open); 9 completed (75%).
Phase mix: 7 late (III/IV) vs 5 early (I/II) (balanced across stages).
Top condition: Spinocerebellar Ataxias (2 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Biohaven Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Biohaven Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 12 archived trials
- Alachua Government Services · 12 trials · 0% recruiting
- Allergy Therapeutics · 12 trials · 0% recruiting
- Ampio Pharmaceuticals. · 12 trials · 0% recruiting
- Angiodynamics · 12 trials · 17% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Biohaven Pharmaceuticals page
12 registered trials is a research-attention snapshot, not an endorsement of Biohaven Pharmaceuticals or any single study.
- None of Biohaven Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Spinocerebellar Ataxias is the condition Biohaven Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Spinocerebellar Ataxias trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Biohaven Pharmaceuticals pipeline card: 12 registered trials from official public datasets.Report a data error.